Showing results (11-20 of 54) with videos related to
Sort By:
Pageof 6
Cancer Epidemiology|October 23, 2018
Intensive treatment and trial participation in elderly acute myeloid leukemia patients: A population-based analysis in The NetherlandsBurak Kalin, Esther N Pijnappel, Michel van Gelder, et al.Clinical Lymphoma, Myeloma & Leukemia|November 4, 2017
Clinical Practice Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL) in The NetherlandsSabina Kersting, Suzanne I M Neppelenbroek, Hein P J Visser, et al.Breast Cancer Research and Treatment|January 29, 2011
Elimination of the chemotherapy resistant subpopulation of 4T1 mouse breast cancer by haploidentical NK cells cures the vast majority of micePeter W H Frings, Catharina H M J Van Elssen, Lotte Wieten, et al.Journal of Hematology & Oncology|February 6, 2015
Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological SocietyFrédéric Baron, Pierre Zachée, Johan Maertens, et al.Oncotarget|May 15, 2018
Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graft-versus-host disease: a multicenter prospective studySophie Servais, Frédéric Baron, Chantal Lechanteur, et al.Journal of Cancer Research and Clinical Oncology|August 31, 2019
Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioningNiels Smedegaard Andersen, Martin Bornhäuser, Martin Gramatzki, et al.Blood Advances|September 16, 2020
Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantationBurak Kalin, Yvette van Norden, Michel van Gelder, et al.Blood Advances|February 10, 2022
Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trialAnnoek E C Broers, Cornelis N de Jong, Katerina Bakunina, et al.Cancer Immunology, Immunotherapy : CII|April 30, 2015
Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2ASubhashis Sarkar, Michel van Gelder, Willy Noort, et al.European Journal of Immunology|September 25, 2010
Klebsiella pneumoniae-triggered DC recruit human NK cells in a CCR5-dependent manner leading to increased CCL19-responsiveness and activation of NK cellsCatharina H M J Van Elssen, Joris Vanderlocht, Peter W H Frings, et al.Pageof 6